Akshat Goel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akshat Goel has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Bethany Tucker
Paediatric Liver, GI and Nutrition Centre and MowatLabs King's College Hospital London UK
2 shared publications- Tassos Grammatikopoulos
Pediatric Liver, GI and Nutrition Centre and Mowat Labs, King’s College Hospital NHS Trust, London, UK
2 shared publications Abdel Douiri
Faculty of Life Sciences and Medicine, King's College, London, UK
1 shared publicationAnil Dhawan
Paediatric Liver, GI & Nutrition Centre and MowatLabs, King's College Hospital, London, UK
1 shared publication- Eirini Kyrana
Roger Williams Institute of Liver Studies King's College London London UK
1 shared publication Gauri Bhonde
Department of Molecular Immunology and Microbiology, ICMR-NIRRCH, Mumbai, India
1 shared publication
Latest Publications
- Open Access
- 4 April 2024
- Published by Wiley in JPGN Reports
- Vol. 5 (3) , 296-302
Odevixibat as an adjunctive treatment for refractory pruritus in rare variants of cholestatic liver disease
Objectives: Odevixibat, a reversible ileal bile acid transport inhibitor, has been shown to reduce serum bile acids (sBA) and pruritus mostly in children with progressive familial intrahepatic cholestasis (PFIC) 1 and 2 in clinical trials and case reports. There are currently no published case reports or series describing its use in rare variants of cholestatic liver disease.Methods: We describe three children with progressive cholestatic liver disease who developed refractory pruritus, who had a genotypic diagnosis of AKR1D1, ABCB4 variant, and PKHD1 and PKHD2 variants; all being variants of unknown significance as per the American College of Medical Genetics and Genomics guidelines.Results: On Odevixibat there was a significant improvement in sBA (absolute change from baseline: −196 and −393 μmol/L) and pruritus in two children with heterozygous AKR1D1 and ABCB4 mutations. The child with ABCB4 variants was found to have features of sclerosing cholangitis along with a diagnosis of Crohn's disease, which represents the first reported usage of Odevixibat in such a case with good response. There was some reported improvement in the third child with PKHD1 and PKHD2 variants; however, we hypothesize that no sustained improvement could be due to severe and progressive nature of the disease. There were no side effects reported and it was well tolerated in all.Conclusion: We suggest that Odevixibat may be used as an adjunctive drug in refractory pruritus and could be started early in the course of disease if clinically and phenotypically indicated.
- 4 April 2024
- Published by Wiley in JPGN Reports
- Vol. 5 (3) , 296-302
Open AccessOdevixibat as an adjunctive treatment for refractory pruritus in rare variants of cholestatic liver disease
Objectives: Odevixibat, a reversible ileal bile acid transport inhibitor, has been shown to reduce serum bile acids (sBA) and pruritus mostly in children with progressive familial intrahepatic cholestasis (PFIC) 1 and 2 in clinical trials and case reports. There are currently no published case reports or series describing its use in rare variants of cholestatic liver disease.Methods: We describe three children with progressive cholestatic liver disease who developed refractory pruritus, who had a genotypic diagnosis of AKR1D1, ABCB4 variant, and PKHD1 and PKHD2 variants; all being variants of unknown significance as per the American College of Medical Genetics and Genomics guidelines.Results: On Odevixibat there was a significant improvement in sBA (absolute change from baseline: −196 and −393 μmol/L) and pruritus in two children with heterozygous AKR1D1 and ABCB4 mutations. The child with ABCB4 variants was found to have features of sclerosing cholangitis along with a diagnosis of Crohn's disease, which represents the first reported usage of Odevixibat in such a case with good response. There was some reported improvement in the third child with PKHD1 and PKHD2 variants; however, we hypothesize that no sustained improvement could be due to severe and progressive nature of the disease. There were no side effects reported and it was well tolerated in all.Conclusion: We suggest that Odevixibat may be used as an adjunctive drug in refractory pruritus and could be started early in the course of disease if clinically and phenotypically indicated.
- Open Access
- 12 October 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (12) , 100935
Transient elastography and von Willebrand factor as predictors of portal hypertension and decompensation in children
- 12 October 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (12) , 100935
Open AccessTransient elastography and von Willebrand factor as predictors of portal hypertension and decompensation in children
- 27 May 2023
- Published by Elsevier in Microbes and Infection
- Vol. 25 (7) , 105165
A novel gut microbiome–immune axis influencing pathology in HCMV infected infants with neonatal cholestasis
- 27 May 2023
- Published by Elsevier in Microbes and Infection
- Vol. 25 (7) , 105165
A novel gut microbiome–immune axis influencing pathology in HCMV infected infants with neonatal cholestasis